Concizumab

Concizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	Tissue factor pathway inhibitor
Clinical data
Trade names	Alhemo
Pregnancy; category	AU: D; ;
Routes of; administration	Subcutaneous
Drug class	Antihemorrhagic
ATC code	B02BX10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D;
Identifiers
CAS Number	1312299-39-0;
DrugBank	DB12820;
UNII	68603V9EAF;
KEGG	D11847;
Chemical and physical data
Formula	C6462H10004N1712O2046S46
Molar mass	145887.81 g·mol−1

Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B.^[5] It is an anti-tissue factor pathway inhibitor.^[5]

Concizumab was approved for medical use in Canada in March 2023.^[4]^[7]

Medical uses

Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.^[5]^[6]

Society and culture

Names

Concizumab is the international nonproprietary name.^[8]

References

^ ^a ^b "Alhemo APMDS". Therapeutic Goods Administration (TGA). 29 September 2023. Archived from the original on 10 March 2024. Retrieved 7 March 2024.
^ "Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 10 March 2024. Retrieved 10 September 2023.
^ "AusPAR: Alhemo". Therapeutic Goods Administration (TGA). 18 March 2024. Retrieved 31 March 2024.
^ ^a ^b "Alhemo Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.
^ ^a ^b ^c ^d "Alhemo (concizumab injection) Product Monograph" (PDF). Health Canada. Archived (PDF) from the original on 3 March 2024. Retrieved 3 March 2024.
^ ^a ^b "Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Archived from the original on 10 March 2024. Retrieved 9 June 2023.
^ "Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Archived from the original on 9 June 2023. Retrieved 9 June 2023 – via Newswire.
^ World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.

Zdroj:https://en.wikipedia.org?pojem=Concizumab
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[Alhemo_APMDS-1] "Alhemo APMDS". Therapeutic Goods Administration (TGA). 29 September 2023. Archived from the original on 10 March 2024. Retrieved 7 March 2024.

[2] "Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 10 March 2024. Retrieved 10 September 2023.

[3] "AusPAR: Alhemo". Therapeutic Goods Administration (TGA). 18 March 2024. Retrieved 31 March 2024.

[Alhemo_PI_CA-4] "Alhemo Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.

[Alhemo_CA_label-5] "Alhemo (concizumab injection) Product Monograph" (PDF). Health Canada. Archived (PDF) from the original on 3 March 2024. Retrieved 3 March 2024.

[Alhemo_SBD-6] "Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Archived from the original on 10 March 2024. Retrieved 9 June 2023.

[7] "Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Archived from the original on 9 June 2023. Retrieved 9 June 2023 – via Newswire.

[WHORecList70-8] World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]